*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) synthesized via <strong>catalytic hydrogenation</strong> and <strong>heterocyclic coupling</strong>. It serves as a critical API in antiretroviral therapy. <strong>Molecular Formula</strong>: C<sub>14</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>; <strong>CAS No.</strong>: 154598-52-6.</p>
<h3>Application</h3>
<ul>
<li><strong>HIV Treatment:</strong> First-line combination therapy for adult and pediatric patients with HIV-1 infection.</li>
<li><strong>Pharmaceutical Manufacturing:</strong> Bulk production of fixed-dose combinations with Tenofovir and Emtricitabine.</li>
</ul>
<h3>Precautions</h3>
<p>Contraindicated in pregnancy during the first trimester due to teratogenicity risks. Requires storage below 25°C in dry, light-resistant conditions. Strict occupational exposure limits apply during synthesis to prevent CNS toxicity.</p>